Combining options in metastatic prostate cancer

Nature Reviews Urology, Published online: 18 July 2019; doi:10.1038/s41585-019-0217-zIntensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

Source: Nature Reviews Urology - July 17, 2019 Category: Urology & Nephrology Authors: Ryan P. Kopp Tomasz M. Beer Source Type: research